Search research articles
Contact Us
Filters
Showing results (191-200 of 201) with videos related to
Page
of 21
Sort By:
The Lancet. Oncology
|
October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Edith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
Blood
|
March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 7, 2022
Listeria monocytogenes Illness and Deaths Associated With Ongoing Contamination of a Multiregional Brand of Ice Cream Products, United States, 2010-2015
Amanda R Conrad, Sheri Tubach, Venessa Cantu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
S G Eckhardt, J Rizzo, K R Sweeney, et al.
Breast Cancer Research and Treatment
|
September 9, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
Breast Cancer Research and Treatment
|
June 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 20, 2016
Implementation of Nationwide Real-time Whole-genome Sequencing to Enhance Listeriosis Outbreak Detection and Investigation
Brendan R Jackson, Cheryl Tarr, Errol Strain, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 201) with videos related to
Sort By:
Page
of 21
The Lancet. Oncology
|
October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Edith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
Blood
|
March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 7, 2022
Listeria monocytogenes Illness and Deaths Associated With Ongoing Contamination of a Multiregional Brand of Ice Cream Products, United States, 2010-2015
Amanda R Conrad, Sheri Tubach, Venessa Cantu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
S G Eckhardt, J Rizzo, K R Sweeney, et al.
Breast Cancer Research and Treatment
|
September 9, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
Breast Cancer Research and Treatment
|
June 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
Javier Cortés, Hope S Rugo, Ahmad Awada, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 20, 2016
Implementation of Nationwide Real-time Whole-genome Sequencing to Enhance Listeriosis Outbreak Detection and Investigation
Brendan R Jackson, Cheryl Tarr, Errol Strain, et al.
Page
of 21